Learn about FEV1pp and the downstream effects of lung function decline in children with severe asthma.
Navigate through this interactive infographic to learn more about why lung function is important to monitor in pediatric patients with asthma and the noninvasive procedures that are available for implementation in clinical practice.
Join Dr. Hanania to understand how to identify patients at risk of fixed airway obstruction in clinical settings.
Join Dr. Celeste Porsbjerg as she explores the mechanisms underlying mucus plugging development as mucociliary clearance. She explains how type 2 cytokines—particularly IL-13—impair this clearance mechanism, leading to mucus plugging, and worsened asthma outcomes.
Learn how FeNO, a noninvasive biomarker for type 2 inflammation, can be used to optimize care for asthma patients.
Join Dr. Celeste Porsbjerg as she discussed on how type 2 inflammation may lead to airway remodeling in asthma, exploring the pathophysiologic mechanisms, that ultimately lead to structural changes and irreversible loss of lung function
Join Drs. Njira Lugogo, Simon Couillard, and Mario Castro for a session exploring the link between pathogenic mucus and impaired lung function in patients with moderate-to-severe asthma and the potential for disease modification with targeted therapy.
In this ADVENT symposium at the 2024 European Respiratory Society conference, Drs. Sharon Dell and Leonard Bacharier discuss the potential domains of on therapy clinical remission in pediatric severe asthma, emphasizing lung function as a key parameter for children.
Learn about the role of type 2 inflammation in the burden and pathophysiology of mucus plugging in severe asthma
Join pediatric respirologist Dr. Sharon Dell and adult respirologist Dr. Simon Couillard as they discuss the prognostic and diagnostic power of asthma biomarkers and their impact on optimizing patient management across all ages.